Dermatology and therapy · 2025
Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balato Anna, Burlando Martina, Campanati Anna, Costanzo Antonio, Chiricozzi Andrea, Gisondi Paolo, Malagoli Piergiorgio, Micali Giuseppe, Psoriasis Working Group
Аннотация
INTRODUCTION: Psoriasis (PsO) is a common inflammatory dermatological condition with a substantial negative impact on patient quality of life. Several biological agents are available for the treatment of PsO, and clinicians and patients must consider various factors when deciding on the most appropriate biological agent.
METHODS: Here, we report a set of consensus statements developed by an Italian PsO advisory board on use of the anti-interleukin-17A biological secukinumab in routine clinical practice.
RESULTS: The statements were developed under three main topics, the first of which was "characteristics of secukinumab and criteria for patient selection to achieve long-term benefits". This statement helps to identify patients most likely to benefit from secukinumab, including biological-naïve patients with moderate PsO; patients with PsO involving sensitive sites; patients in whom biosimilar anti-tumour necrosis factor-alpha treatment has proved ineffective; patients at high risk of developing psoriatic arthritis; lean or normal-weight patients; patients with active disease receiving conventional disease-modifying antirheumatic drugs; and patients with comorbidities, including cardiovascular disease. Under the second topic, "strategies to maintain secukinumab effectiveness in the long term", the advisors highlighted the importance of patient support to promote adherence; weight control; understanding that PsO can worsen for reasons unrelated to treatment; and understanding that appropriate treatment should depend on the severity of any disease worsening. The third topic, "strategies for patient support to promote adherence to therapy", noted the importance of patient education, accurate disease assessments and treatment tailoring.
CONCLUSION: These consensus statements will help guide dermatologists in the selection of patients with PsO for whom secukinumab is the most appropriate treatment in real-world clinical practice in Italy.
METHODS: Here, we report a set of consensus statements developed by an Italian PsO advisory board on use of the anti-interleukin-17A biological secukinumab in routine clinical practice.
RESULTS: The statements were developed under three main topics, the first of which was "characteristics of secukinumab and criteria for patient selection to achieve long-term benefits". This statement helps to identify patients most likely to benefit from secukinumab, including biological-naïve patients with moderate PsO; patients with PsO involving sensitive sites; patients in whom biosimilar anti-tumour necrosis factor-alpha treatment has proved ineffective; patients at high risk of developing psoriatic arthritis; lean or normal-weight patients; patients with active disease receiving conventional disease-modifying antirheumatic drugs; and patients with comorbidities, including cardiovascular disease. Under the second topic, "strategies to maintain secukinumab effectiveness in the long term", the advisors highlighted the importance of patient support to promote adherence; weight control; understanding that PsO can worsen for reasons unrelated to treatment; and understanding that appropriate treatment should depend on the severity of any disease worsening. The third topic, "strategies for patient support to promote adherence to therapy", noted the importance of patient education, accurate disease assessments and treatment tailoring.
CONCLUSION: These consensus statements will help guide dermatologists in the selection of patients with PsO for whom secukinumab is the most appropriate treatment in real-world clinical practice in Italy.